Bolt Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Bolt Biotherapeutics, Inc. on May 27, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Redwood City, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
As of the record date (April 15, 2025), 38,339,697 shares were entitled to vote, with 24,362,318 shares represented at the meeting. The following proposals were voted upon:
- Director Elections: Laura Berner and Brian O'Callaghan were elected as Class I directors to serve until the 2028 Annual Meeting.
- Independent Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Reverse Stock Split: Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split of the Company's issued and outstanding common stock.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the specific ratio of the approved reverse stock split, as the filing confirms approval but does not state the ratio.
- Confirm the effective date of the reverse stock split and any resulting changes to the trading symbol or par value.
- Review the definitive proxy statement (Schedule 14A filed April 25, 2025) for detailed biographies of the newly elected directors and the rationale for the auditor selection.
- Monitor the Company's capital structure post-split to ensure compliance with Nasdaq Capital Market listing requirements.